Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

HealthCare Global Enterprises - Growth momentum to continue - ICICI Securities

Posted On: 2021-06-21 16:24:24 (Time Zone: UTC)


HealthCare Global Enterprises' (HCG) Q4FY21 performance was broadly inline with our estimates driven by continued sequential recovery in the oncology hospital segment revenues that grew 8.8% QoQ. However, higher than expected costs suppressed EBITDA margin to 13.2% (I-Sec: 14.5%). We expect the recovery trend to continue and normalcy to be achieved by H2FY22E. Recent capital infusion has removed the key overhang of high leverage with repayment of debt from the fund raising exercise. We remain positive on the stock as the company is poised to grow positively hereon and strengthening of balance sheet with no major capex plan in near term. However, recent run up in the stock has limited the upside potential, hence we downgrade to ADD from Buy with a revised target price of Rs206/share.

- Growth momentum in revenue continues: Consolidated revenues grew 10.2% with improving momentum in the hospital business. Oncology revenues grew 11.7% YoY and 8.8% QoQ with higher AROPB (+6.0% YoY). While, Milann (infertility) segment revenues declined 12.4% YoY, it also improved QoQ by reporting growth of 7.6%. Karnataka cluster grew 11.1%. Gujarat cluster grew 4.7%. Maharashtra cluster grew 37.3% YoY. We expect this growth momentum to continue for the coming quarters with ongoing vaccinations and receding 2nd wave of the pandemic. We believe Gujarat and Maharashtra clusters would be the key growth drivers over FY21-FY23E. East India cluster witnessed growth of 11.7% YoY.

- Margin set to normalise with improving performance: EBITDA margin dropped 10bps YoY and 60bps QoQ to 13.2% with 210bps drop in the gross margin. Effective cost control on personnel and S,G&A fronts helped offset the decline of gross margin to some extent. We expect EBITDA margin to normalise by H1FY22 with positive revenue growth and estimate 460bps improvement over FY21-FY23E.

- Outlook: Over all we expect 20.5% revenue and 39.6% EBITDA CAGR over FY21-FY23 on a COVID-19 impacted FY21 base. Capex phase is complete and no new projects are planned in the near term. We expect losses from new centres to narrow improving overall profitability. The recent fund raise has helped in paring down the leverage significantly, with net debt dropping to below Rs3bn.

- Valuations and risks: We broadly maintain our estimates and remain positive on the stock considering focus on niche oncology healthcare services and potential to grow faster with strengthening of balance sheet post the recent fund raise. Considering recent run up in stock price, we downgrade the stock to ADD from Buy with a revised target of Rs206/share based on 16xFY23E EBITDA (earlier: Rs192/share). We have raised the target multiple to 16x from 15x considering improving business performance and strengthening balance sheet. Key downside risks: Higher competition in oncology, and delay in operational turnaround of new centres.

Shares of HealthCare Global Enterprises Ltd was last trading in BSE at Rs.194.2 as compared to the previous close of Rs. 192.3. The total number of shares traded during the day was 3330 in over 345 trades.

The stock hit an intraday high of Rs. 199 and intraday low of 188.2. The net turnover during the day was Rs. 647364.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.


Other Headlines:

Ambuja Cements Ltd: Q2CY21 Result update - YES Securities

Q1FY22 Result Update - Polycab India - ICICI Direct

Q1FY22 Result Update - Hindustan Zinc - ICICI Direct

Federal Bank - Q1FY22 First Cut - ICICI Direct

Q1FY22 Result Update - Biocon Ltd - ICICI Direct

IPO Review - Glenmark Life Sciences Ltd - ICICI Direct

JSW Steel - Q1FY22 First Cut - ICICI Direct

Crompton Greaves Consumer Electricals - Q1FY22 First Cut - ICICI Direct

Q1FY22 Result Update - CSB Bank - ICICI Direct

SKF India - Q1FY22 First Cut - ICICI Direct

Company Update - Gandhi Special Tubes - ICICI Direct

Q1FY22 Result Update - Hindustan Unilever - ICICI Direct

Q1FY22 Company Update - Mphasis - ICICI Direct

Maintain REDUCE on Hindustan Unilever - Steady performance continues - HDFC Securities

Maintain ADD on Havells India - Robust performance despite the odds - HDFC Securities

Maintain BUY on Bajaj Auto - Laying the ground for future technologies - HDFC Securities

Maintain BUY on UltraTech Cement - UltraHigh! Margin at its best ever; outlook strong - HDFC Securities

ICICI Lombard Report - Not in the pink: spike in health claims affects loss ratio - HDFC Securities

Hindustan Zinc - Higher commodity continues to propel earnings - ICICI Securities

ICICI Lombard General Insurance Company - Q1FY22 Update - ICICI Direct

UltraTech Cement - EBITDA/te inches to highest-ever Rs1,600/te - ICICI Securities

Arvind Fashions Ltd - A step in the right direction - ICICI Securities

CEAT - RM cost pressures likely to stay elevated - ICICI Securities

Hindustan Unilever - (Re) Investing (margins) for growth - ICICI Securities

Mahindra CIE Automotive - Growth outlook remains healthy - ICICI Securities

Bajaj Auto - Tough quarter; export outlook remains solid - ICICI Securities

Mphasis - Q1 FY22 first cut - YES Securities

Can Fin Homes - Q1 FY22 first cut - YES Securities

Sterlite Technologies - Q1 FY22 first cut - YES Securities

IndiaMart - Q1 FY22 first cut (Current Rating: BUY) - YES Securities

Schaeffler Q2CY21 call highlights (Rating: NOT RATED) - YES Securities

CEAT 1QFY22 call highlights (Rating: NOT RATED) - YES Securities

Bajaj Auto 1QFY22 first cut & call highlights (Rating: NOT RATED) - YES Securities

ICICI Lombard - Q1 FY22 Result Report - YES Securities

Hindustan Unilever - Q1 FY22 Result Report - YES Securities

Avenue Supermart - Q1 FY22 Result Report - YES Securities

Ultratech Cement - Q1 FY22 Result Report - YES Securities

Havells India - Q1 FY22 Result Report - YES Securities

Polycab India - Q1 FY22 Result Report - YES Securities

Q1FY22 Result Update - Bajaj Auto - ICICI Direct

Q1FY22 Result Update - Sterlite Technologies - ICICI Direct

Q1FY22 Result Update - UltraTech Cement - ICICI Direct

Biocon - Q1FY22 First Cut - ICICI Direct

Gladiator Stocks - Bharti Airtel - ICICI Direct

Q1FY22 Result Update - Rallis India - ICICI Direct

Q1FY22 Result Update - Havells India - ICICI Direct

Q1FY22 Result Update - Syngene International - ICICI Direct

Sterlite Technologies - Q1FY22 First Cut - ICICI Direct

Bajaj Auto - Q1FY22 First Cut - ICICI Direct

UltraTech Cement - Q1FY22 First Cut - ICICI Direct


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020